<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381147</url>
  </required_header>
  <id_info>
    <org_study_id>S-340-14-6-1-PU-11</org_study_id>
    <nct_id>NCT00381147</nct_id>
  </id_info>
  <brief_title>Use of Clarithromycin in Mustard-Induced Bronchiolitis</brief_title>
  <official_title>Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqiyatallah Medical Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baqiyatallah Medical Sciences University</source>
  <brief_summary>
    <textblock>
      We looked for the effectiveness of low-dose long-term prescription of clarithromycin in&#xD;
      mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Acute Obliterating Bronchiolitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  His/her own will to participate&#xD;
&#xD;
          -  Documented chemical exposure&#xD;
&#xD;
          -  Clinical, spirometric and radiological findings were compatible with BO on High&#xD;
             Resolution Computed Tomography (HRCT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any drug reactions during the trial&#xD;
&#xD;
          -  history of sensitivity to macrolides&#xD;
&#xD;
          -  diarrhea, gray stool, jaundice, eosinophilia, acute cholestatic hepatitis, pruritis,&#xD;
             dark urine, abdominal pain, osteomatosis, depression, taste change, behavioural&#xD;
             changes, early fatigue, odynophagia, glossitis , dizziness&#xD;
&#xD;
          -  co-adminstration of: terfenadine, theophylline, carbamazepine, ergotamine,&#xD;
             dihydroergotamine, warfarin, cisapride, digoxin, triazolam, phenytoin, steroids, any&#xD;
             immunosuppressive, any systemic antibiotics&#xD;
&#xD;
          -  using drugs that he/she cannot discontinue&#xD;
&#xD;
          -  using drugs with potential interaction&#xD;
&#xD;
          -  subject will to exit from the trial&#xD;
&#xD;
          -  history of lobe resection of lung&#xD;
&#xD;
          -  history of exacerbation in the last month prior to the beginning of trial&#xD;
&#xD;
          -  continuous need to oxygen&#xD;
&#xD;
          -  use of corticosteroids in last week prior to the trial beginning&#xD;
&#xD;
          -  Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an&#xD;
             infection that necessitated the use of an antibiotic&#xD;
&#xD;
          -  exacerbating of subjects&#xD;
&#xD;
          -  creatinine srum level more than normal&#xD;
&#xD;
          -  increasing ALT, AST levels&#xD;
&#xD;
          -  total bilirubin more twice than normal&#xD;
&#xD;
          -  subjects who did not use their drugs properly&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mostafa Ghanei, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baqiyatallah Medical Sciences University</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 26, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2006</study_first_posted>
  <last_update_submitted>January 6, 2009</last_update_submitted>
  <last_update_submitted_qc>January 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

